English | 简体中文 | 繁體中文 | 한국어 | 日本語
2025年4月10日 13時57分 JST
Share:
Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy

SINGAPORE, Apr 10, 2025 - (ACN Newswire) - April 9, Hebe Biotechnology Pte Ltd (“Hebe Bio”), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company’s next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy designed to enhance efficacy and tolerability, addressing the global obesity challenge.

Strategic Leadership for a Transformative Therapy

Dr. Hentze brings over two decades of experience in pharmaceutical development, specializing in oncology, metabolic disorders, and biologics. His background spans academic research (IMCB, NTU), biotech ventures (S*BIO, ES Cell International, ASLAN), and large pharmaceutical players (Schering-Plough, MSD). Most recently, he served as Associate Director of Translational Sciences at EDDC (A*STAR).

At Hebe Bio, Dr. Hentze will spearhead preclinical and translational development, guiding clinical trial readiness, regulatory strategy, and strategic partnerships to accelerate the GLP-1 RA program’s global commercialization.

Sam Lim, MD, PhD, MBA, CEO of Hebe Bio, remarked, “We are thrilled to welcome Hannes to our leadership team. His deep expertise in metabolic drug development and his visionary approach align perfectly with our mission to deliver transformative therapies. His leadership will be pivotal as we accelerate our GLP-1 RA candidate, which has the potential to redefine standards in weight management and healthspan extension.”

Advancing Innovation in Metabolic Health

Hebe Bio’s GLP-1 RA therapy integrates cutting-edge science to optimize fat loss in the context of maintaining muscle mass, while minimizing common side effects associated with existing therapies. Preclinical data on Hebe Bio’s lead molecules have demonstrated superior efficacy and tolerability, positioning it as a next-generation solution for truly sustainable, healthspan-extending weight loss therapy.

Dr. Hentze expressed enthusiasm about his new role at Hebe Bio: “Joining Hebe Bio is a unique opportunity to make a real impact in a critical area of global health. Our GLP-1 RA candidate has the potential to shift the obesity treatment paradigm, and I look forward to collaborating with the exceptional Hebe Bio team, and our global partners to bring this therapy to patients worldwide.”

About Hebe Biotechnology Pte Ltd

Hebe Biotechnology is a Singapore-headquartered biopharmaceutical company dedicated to pioneering next-generation therapies for metabolic and chronic diseases. By combining advanced research with strategic global partnerships, Hebe Bio is committed to delivering patient-centric solutions that address unmet medical needs.

Media Contact:

Ms Kung
Bright International Communications Limited
Email: ir@brightcommns.com
Mobile: +852 4637 1627
Website: www.hebebio.sg



トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
富士通、特化型AIエージェントでグローバルサプライチェーンを最適化するソリューションが、ビジネスを変革する先進事例として選定 
July 14, 2025 11:00 HKT/SGT
エーザイ、痛風治療剤「URECE」(一般名:ドチヌラド)を中国において新発売 
July 14, 2025 09:00 HKT/SGT
「天壇映像世界巡回展・東京ステーション」が成功裏に終わり、中国映画が高い評価を獲得 
July 11, 2025 13:00 HKT/SGT
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering 
July 11, 2025 09:28 HKT/SGT
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation 
July 11, 2025 08:00 HKT/SGT
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration 
July 10, 2025 07:00 HKT/SGT
エーザイ、厚生労働省の中央社会保険医療協議会による「レケンビ」の費用対効果評価について 
July 9, 2025 14:50 HKT/SGT
エーザイ、CDP から「サプライヤー・エンゲージメント評価」において最高評価である「サプライヤー・エンゲージメント・リーダー」に選定 
July 8, 2025 09:00 HKT/SGT
三菱重工、北海道電力苫東厚真発電所向け国内最大規模のCO₂回収設備の基本設計を受注 
July 7, 2025 11:30 HKT/SGT
アリックスパートナーズ、2025年版グローバル・リスク調査の結果を発表 
July 7, 2025 11:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575